Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lünemann, J. D.
Right arrow Articles by Zipp, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lünemann, J. D.
Right arrow Articles by Zipp, F.
Related Collections
Right arrow Multiple sclerosis
Neurology 2001;57:1132-1134
© 2001 American Academy of Neurology
Brief Communications

Downregulation of transforming growth factor-ß1 in interferon-ß1a-treated MS patients

J. D. Lünemann, MD, O. Aktas, MD, P. Gniadek, MD, R. Zschenderlein, MD and F. Zipp, MD

From the Division of Neuroimmunology, Department of Neurology, Charité University Hospital, Berlin, Germany.

Address correspondence and reprint requests to Dr. F. Zipp, Division of Neuroimmunology, Department of Neurology, Charité, Schumannstrasse 20/21, 10117 Berlin, Germany; e-mail: frauke.zipp{at}charite.de

The authors report an intense downregulation of transforming growth factor-ß1 (TGF-ß1) serum levels 4 weeks from start of interferon-ß1a (IFN-ß1a) treatment at 44 µg/week in 271 patients with relapsing–remitting MS, which was still present after 1 year (p < 0.001). In line with previous data, interleukin-10 serum levels did not vary significantly. These results indicate that the immunomodulatory effects of IFN-ß might not be restricted to the postulated anti-inflammatory mechanisms and address the role of TGF-ß in the pathogenesis of MS.




This article has been cited by other articles:


Home page
 Mult SclerHome page
M Krakauer, P Sorensen, M Khademi, T Olsson, and F Sellebjerg
Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-{beta} treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression
Multiple Sclerosis, June 1, 2008; 14(5): 622 - 630.
[Abstract] [PDF]

Home page
 NeurologyHome page
V. W. Yong
Differential mechanisms of action of interferon-{beta} and glatiramer acetate in MS
Neurology, September 24, 2002; 59(6): 802 - 808.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by AAN Enterprises, Inc.